Article Text

Download PDFPDF
Brief encounters
  1. Helen Ward,
  2. Rob Miller, Editors

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Genital warts affect quality of life

    A national human papillomavirus (HPV) immunisation programme will start in the UK in September 2008 and will commence with vaccination of 12–13 year old girls. Two HPV vaccines are potentially available. Both protect against HPV types 16 and 18 (which cause >70% of all cases of cervical carcinoma); additionally, one also protects against types 6 and 11 (which cause >95% of genital warts). Woodhall et al measured the impact of genital warts on health-related quality of life (HRQoL) to assess potential benefits of the quadrivalent vaccine. Patients attending a genitourinary medicine (GUM) clinic with current genital warts had lower HRQoL scores than controls, the differences being most marked in young women. The authors suggest that the potential added benefit of preventing most cases of genital warts by HPV vaccination should be considered when decisions are made about which HPV vaccine to use in the UK. See page 161

    Primary care for STI

    Neale et al carried …

    View Full Text

    Linked Articles